Table 1.
Clinical characteristics of chronic lymphocytic leukemia (CLL) patients.
| Patient | Sex/Age | Stage | IGHV Mutation | FISH | Karyotype | Therapy |
|---|---|---|---|---|---|---|
| 1 | M/71 | A | M | Trisomy 12 | 1 abnormality | None |
| 2 | M/63 | A | ND | 13q- | Complex | None |
| 3 | M/90 | A | M | ND | ND | None |
| 4 | M/88 | A | M | 13q- | Normal | None |
| 5 | M/76 | A | ND | 13q- | Normal | None |
| 6 | M/87 | C | M | 17p-, 13q- | Normal | None |
| 7 | M/66 | B | M | 13q- | 2 abnormalities | None |
| 8 | M/71 | A | ND | 13q- | Normal | None |
| 9 | M/71 | A | M | 11q-, 13q- | 1 abnormality | None |
| 10 | F/69 | B | ND | 13q- | Normal | None |
| 11 | F/74 | A | UM | 13q- | Normal | None |
| 12 | F/74 | A | M | Normal | Normal | None |
| 13 | F/78 | A | M | 13q- | Normal | None |
| 14 | M/73 | A | M | Normal | Normal | None |
| 15 | F/68 | A | ND | 13q- | 1 abnormality | None |
| 16 | F/62 | B | UM | 13q- | Normal | None |
| 17 | F/69 | A | M | 13q- | Normal | None |
| 18 | F/87 | A | ND | 13q- | Normal | None |
| 19 | F/83 | A | ND | Normal | Normal | None |
| 20 | M/86 | A | ND | Normal | Normal | None |
| 21 | M/86 | A | M | Trisomy 12 | Complex | None |
| 22 | M/82 | A | ND | 11q-, 13q- | Normal | None |
| 23 | F/77 | A | UM | 13q- | Failure | None |
| 24 | M/74 | A | ND | 13q- | 2 abnormalities | None |
| 25 | M/86 | A | M | 13q- | ND | None |
| 26 | F/76 | A | UM | 11q-, 13q- | Normal | None |
| 27 | F/88 | A | ND | ND | ND | None |
| 28 | F/64 | A | M | 13q- | Normal | None |
| 29 | M/70 | A | ND | 13q- | Normal | None |
| 30 | M/75 | A | M | 13q- | Normal | None |
| 31 | F/67 | A | ND | 13q- | Normal | None |
| 32 | F/74 | A | ND | 13q- | 1 abnormality | None |
| 33 | M/76 | A | ND | 13q- | Normal | None |
| 34 | M/68 | B | ND | 11q- | Complex | None |
| 35 | F/85 | A | M | 13q- | Normal | None |
| 36 | F/70 | A | ND | 13q- | Normal | None |
| 37 | F/52 | A | ND | 13q- | Normal | None |
| 38 | F/79 | A | ND | 13q- | Normal | None |
| 39 | F/54 | B | ND | Trisomy 12 | 1 abnormality | None |
| 40 | M/76 | A | M | 13q- | Normal | None |
| 41 | F/57 | A | ND | 13q- | Normal | None |
| 42 | M/72 | A | M | 13q- | ND | None |
| 43 | F/84 | A | ND | Normal | Normal | None |
| 44 | F/80 | B | ND | 11q- | 1 abnormality | None |
| 45 | M/62 | A | ND | Normal | Normal | None |
| 46 | M/75 | B | UM | Trisomy 12 | 1 abnormality | None |
| 47 | F/73 | A | ND | 13q- | Failure | None |
| 48 | M/59 | A | ND | ND | ND | None |
| 49 | F/75 | A | ND | 13q- | Normal | None |
| 50 | M/61 | B | ND | 13q-, Trisomy 12 | Complex | None |
| 51 | F/82 | A | ND | 13q- | Normal | None |
| 52 | F/53 | A | UM | 13q- | 2 abnormalities | None |
| 53 | M/71 | A | UM | 11q-, 13q- | ND | None |
| 54 | F/96 | A | UM | Trisomy 12 | 1 abnormality | None |
| 55 | M/72 | A | ND | Normal | Normal | None |
| 56 | F/85 | A | ND | Normal | 2 abnormalities | None |
| 57 | F/69 | A | M | Normal | Normal | None |
| 58 | F/51 | B | UM | 11q-, 13q- | 1 abnormality | None |
| 59 | M/63 | B | UM | 13q- | Normal | None |
| 60 | M/70 | B | UM | 11q-, 13q- | 2 abnormalities | None |
| 61 | F/80 | B | ND | 11q- | 1 abnormality | Ibrutinib/relapse |
| 62 | M/62 | B | UM | 11q-, 13q- | 1 abnormality | FCR/relapse |
| 63 | F/78 | A | M | 13q- | 1 abnormality | RCb/relapse |
| 64 | M/54 | B | UM | 13q- | 2 abnormalities | Ibrutinib/remission |
| 65 | F/78 | C | UM | 17p-, 13q-, Trisomy 12 | Complex | Ibrutinib/remission |
| 66 | M/76 | B | ND | 17p-, 13q- | 2 abnormalities | Ibrutinib/relapse |
| 67 | M/80 | B | UM | 17p-, 13q- | Complex | Ibrutinib/relapse |
| 68 | M/54 | C | UM | 17p-, 11q- | Complex | Ibrutinib/remission |
| 69 | F/72 | B | UM | 17p-, Trisomy 12 | Complex | Ibrutinib/remission |
| 70 | M/92 | A | ND | ND | ND | Cb/relapse |
| 71 | M/66 | C | UM | 13q-, Trisomy 12 | Complex | Ibrutinib/remission |
| 72 | M/70 | A | M&UM | 11q- | Failure | FCR/relapse |
| 73 | F/77 | A | M | Normal | ND | FC/relapse |
| 74 | M/88 | C | UM | 17p-, Trisomy 12 | Normal | RCb/remission |
| 75 | M/82 | C | UM | 11q-, 13q- | Complex | BR/relapse |
| 76 | M/79 | B | UM | Normal | Normal | BR/remission |
| 77 | M/64 | A | UM | Trisomy 12 | 1 abnormality | FCR/cyclosporine/remission |
| 78 | F/75 | B | M | 13q-, Trisomy 12 | 1 abnormality | FCR/remission |
| 79 | F/84 | B | ND | Normal | Complex | Ibrutinib/remission |
| 80 | F/64 | B | UM | 13q- | Normal | FCR/remission |
| 81 | M/69 | B | ND | 11q- | Complex | FCR x4/remission |
| 82 | M/75 | B | M | Trisomy 12 | 1 abnormality | BR/remission |
| 83 | M/74 | C | M | 11q-, 13q- | ND | MiniCHOP/remission |
| 84 | M/81 | C | M | 11q-, 13q- | ND | Alemtuzumab/relapse |
| 85 | M/75 | B | UM | 17p-, 13q- | 2 abnormalities | FCR x2/relapse |
Unmutated (UM); mutated (M); not done (ND). Fluorescent in situ hybridization (FISH) detecting 13q14 deletion (13q-), 11q22 deletion (11q-), 17p13 deletion (17p-) and trisomy 12. Chromosomal abnormalities are defined by conventional karyotyping (complex karyotype for ≥3 chromosomal abnormalities). Fludarabine, cyclophosphamide and rituximab (FCR). Rituximab and chlorambucil (RCb). Chlorambucil (Cb). Fludarabine and cyclophosphamide (FC). Bendamustine and rituximab (BR). Cyclophosphamide, vincristine and prednisone (MiniCHOP).